Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor

被引：37

作者：

Jacobson, Eric M. ^{[2
]}

Hugo, Eric R. ^{[1
]}

Tuttle, Traci R. ^{[1
]}

Papoian, Ruben ^{[3
]}

Ben-Jonathan, Nira ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA

[2] Univ Cincinnati, Div Endocrinol Diabet & Metab, Cincinnati, OH 45267 USA

[3] Univ Cincinnati, Ctr Drug Discovery, Cincinnati, OH 45237 USA

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2010年 / 21卷 / 11期

关键词：

GROWTH-HORMONE RECEPTOR; POLYMERASE-CHAIN-REACTION; SMALL-MOLECULE LIGANDS; GENE-EXPRESSION; MESSENGER-RNA; CELL-LINES; PLACENTAL-LACTOGEN; PROGNOSTIC-SIGNIFICANCE; EXTRACELLULAR DOMAIN; ANDROGEN RECEPTOR;

D O I：

10.1016/j.tem.2010.08.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Breast and prostate cancers are hormone-sensitive malignancies that afflict millions of women and men. Although prolactin (PRL) is known as a survival factor that supports tumor growth and confers chemoresistance in both cancers, its precise role in these tumors has not been studied extensively. Growth hormone and placental lactogen also bind PRL receptor (PRLR) and mimic some of the actions of PRL. Blockade of the PRLR represents a novel treatment for patients with advanced breast or prostate cancer with limited therapeutic options. This review discusses different approaches for generating PRLR antagonists. Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications.

引用

页码：691 / 698

页数：8

共 80 条

[21] HEIZ2-Positive breast cancer - Current and future treatment strategies [J].

Engel, Ryan H. ;

Kaklamani, Virginia G. .

DRUGS, 2007, 67 (09) :1329-1341

[22] Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter [J].

Fang, Feng ;

Antico, Giovanni ;

Zheng, Jiamao ;

Clevenger, Charles V. .

BMC BIOTECHNOLOGY, 2008, 8 (1)

[23] Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts [J].

Ferretti, C. ;

Bruni, L. ;

Dangles-Marie, V. ;

Pecking, A. P. ;

Bellet, D. .

HUMAN REPRODUCTION UPDATE, 2007, 13 (02) :121-141

[24]

FIELDS K, 1993, LAB INVEST, V68, P354

[25] High-throughput screening: Update on practices and success [J].

Fox, Sandra ;

Farr-Jones, Shauna ;

Sopchak, Lynne ;

Boggs, Amy ;

Nicely, Helen Wang ;

Khoury, Richard ;

Biros, Michael .

JOURNAL OF BIOMOLECULAR SCREENING, 2006, 11 (07) :864-869

[26] Basal growth hormone concentrations in blood and the risk for prostate cancer:: A case-control study [J].

Fuhrman, B ;

Barba, M ;

Schünemann, HJ ;

Hurd, T ;

Quattrin, T ;

Cartagena, R ;

Carruba, G ;

Muti, P .

PROSTATE, 2005, 64 (02) :109-115

[27] Growth hormone receptor is expressed in human breast cancer [J].

Gebre-Medhin, M ;

Kindblom, LG ;

Wennbo, H ;

Törnell, J ;

Meis-Kindblom, JM .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (04) :1217-1222

[28]

GINSBURG E, 1995, CANCER RES, V55, P2591

[29] Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? [J].

Goffin, Vincent ;

Touraine, Philippe ;

Culler, Michael D. ;

Kelly, Paul A. .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (10) :571-581

[30] Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo [J].

Gu, Lei ;

Vogiatzi, Paraskevi ;

Puhr, Martin ;

Dagvadorj, Ayush ;

Lutz, Jacqueline ;

Ryder, Amy ;

Addya, Sankar ;

Fortina, Paolo ;

Cooper, Carlton ;

Leiby, Benjamin ;

Dasgupta, Abhijit ;

Hyslop, Terry ;

Bubendorf, Lukas ;

Alanen, Kalle ;

Mirtti, Tuomas ;

Nevalainen, Marja T. .

← 1 2 3 4 5 6 7 8 →